Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Trial of Single-agent CNTO 888 in Metastatic Castration-Resistant Prostate Cancer
2009-011251-48Phase 2Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carlumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Biologics B.V. Primary endpoint: Composite response rate. Started Jul 2009; status: completed.
02
Drugs
carlumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2009-011251-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011251-48.